Spotlight -

Concierge Medicine Forum|

News|Videos|May 20, 2025

Compounded GLP-1 RA drugs: What about prices? Are compounded drugs cheaper or more expensive than manufacturers’ versions?

Author(s)Richard Payerchin

Fact checked by: Todd Shryock

APC CEO Scott Brunner, CAE, discusses compounding drugs, including the GLP-1 RA antidiabetes and antiobesity medications.

GLP-1 RA drugs have made headlines for improving health — and for high costs. Compounded versions may be less expensive, but that is not the case with every drug. Scott Brunner, CAE, CEO of the Alliance for Pharmacy Compounding, explains the context of cost for compounded medicines.

Newsletter

Stay informed with the Medical Economics eNewsletter, delivering expert insights, financial strategies, practice management tips, and technology trends tailored for today’s physicians.

Related Content

Roger Marshall's practice sued 700 patients over unpaid bills; patients trust their own doctor over Washington; two bills target primary care pay and AI denials — Morning Medical Update Weekly Recap

Sen. Roger Marshall's practice sued 700 patients over unpaid bills; patients trust their own doctor over Washington; two bills target primary care pay and AI denials — Morning Medical Update Weekly Recap

ByAustin Littrell

September 11th 2026

What you need to know about bonds in your retirement portfolio

BySteven Podnos MD, CFP

September 11th 2026

Hospital consolidation: Making primary care more integrated — and more expensive

ByRobert Resnik, M.D., MBA

September 11th 2026

What physicians should know about community health workers before Medicaid work requirements take effect © Iryna - stock.adobe.com

What physicians should know about community health workers before Medicaid work requirements take effect

ByAustin Littrell

September 11th 2026

Trump says $500 checks will go to 1 million ACA enrollees starting in October © Gage Skidmore - Flickr

Trump says $500 checks will go to 1 million ACA enrollees starting in October

ByAustin Littrell

September 10th 2026

Latest CME

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Jordan Axelrad, MD, MPH, FACG, FCCF; Jessica R. Allegretti, MD, MPH; Florian Rieder, MD

Trending on Medical Economics

Sen. Roger Marshall's obstetrics practice sued more than 700 patients over unpaid bills

Bipartisan Senate bill would send $10 billion to primary care and rework how Medicare values physician work

Trump says $500 checks will go to 1 million ACA enrollees starting in October

The hidden data problem costing physicians time, referrals and patients

Physicians who survive life-threatening illness often clash with their own patient identity